New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine.
about
Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutationsRegulated and Liver-Specific Tamarin Alpha Interferon Gene Delivery by a Helper-Dependent Adenoviral VectorEvolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapyAlpha Interferon Inhibits Hepatitis C Virus Replication in Primary Human Hepatocytes Infected In VitroInterferon Alpha Treatment and Thyroid DysfunctionPharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsInterferon alpha-2a treatment for serpiginous choroiditis.Evaluated outcomes in patients with Chronic Hepatitis C.Interferon induced thyroiditis.Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cellsPneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literatureHepatitis C and interferon induced thyroiditis.Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C.Regulation of cysteinyl leukotriene receptor 2 expression--a potential anti-tumor mechanism.Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C.Ribavirin and IFN-alpha combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis BTherapeutic implications of hepatitis C virus resistance to antiviral drugs.Experimental and emerging therapies for chronic hepatitis C virus infection.Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report.IFN-α mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms.Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart.A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitisThe effects of pegylated interferon-α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary reportType I interferons and their therapeutic role in Th2-regulated inflammatory disorders.Pegylated Interferon-α Modulates Liver Concentrations of Activin-A and Its Related Proteins in Normal Wistar Rat.Hla-Cw7 allele as predictor of favorable therapeutic response to interferon-alpha in patients with chronic hepatitis C.Established and emerging therapies for the treatment of viral hepatitis.PharmGKB summary: peginterferon-α pathway.When Benign Tumors Mimic Malignancies: A Case of Lymphangiomatosis Masquerading as Metastatic Disease.Interaction of interferon alpha therapy with thyroid function tests in the management of hepatitis C: a case report.Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel diseaseOphthalmologic complications of antiviral therapy in hepatitis C treatment.Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients.Type I IFNs and their role in the development of autoimmune diseases.Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE.Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report.Mechanism of action of ribavirin in the treatment of chronic hepatitis C.Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review.Soluble inflammatory markers as predictors of virological response in patients with chronic hepatitis C virus infection treated with interferon-α plus ribavirin.Cognitive impairment in hepatitis C patients on antiviral therapy.
P2860
Q27469554-9095F942-844E-4231-A52C-4A7732FE4BDFQ27469612-65B4D4B7-D6DD-4879-8FCC-074CAEC14BCDQ27469719-E9E7A8FA-1F9E-463B-9255-C3BC7B4BE8A4Q27473519-D884D539-7CFF-4AB6-A6BE-1A3E61EC3FBFQ27483686-28D41789-3ABC-4858-A1E2-55481637CF6DQ30365599-C480E756-FF4E-43EE-9A29-18F63EEED946Q33213523-5A0C1B4E-4B25-496A-9327-D5E8F97B232BQ33596752-CF476661-B3DA-4632-8604-1C3141D705D9Q33636049-4556319A-BAE0-4980-8F13-56498D9FD281Q33647345-BE32EC40-B6FF-479A-946C-E02426EB21F0Q33658701-4EC3B9A8-A302-4E6F-A7BE-66C334F77FF5Q33716540-B3C1D3BE-1E38-47FB-9C0D-776A2A53B1A9Q33867071-B5203CF6-07AA-472C-B941-DE9AA5251914Q34110714-8667C95F-9950-4621-A0A2-A235BFA8A404Q34134933-ABF33C6A-5781-44F2-8CB5-125D8BC54283Q34225464-6BFA3081-DBD9-4D03-8AAD-A077527ABD80Q34409020-35A641EB-9BC6-4EB0-886D-833D9EAE7703Q34481629-49A499DB-4F3F-40AF-A892-E79E74DFC212Q34985921-34AF3EEE-3C0E-4DFF-815B-F101E288FB26Q35020174-8FE7182C-0992-4D3D-B199-4B860E0FE62BQ35045446-69CF6BEF-830A-4016-8059-AC054C9BBA5CQ35596154-046C9868-B241-45DC-8DC9-32EB4B097BA9Q35674832-C91B4A71-AF95-47E0-B53F-9275E93A77A8Q35753508-1349796E-459D-4995-B27B-05AA254A6563Q35864762-476D1694-9767-403F-995D-2C392D40742AQ36405322-ED638370-8006-4EB3-94C9-866EACEB133FQ36478120-F58A4FD5-247C-4ACD-8930-DAA59F497899Q36590755-FC870DAA-9434-490C-BFA5-CC1E005DF799Q36816681-10D6EC06-13A0-46A9-9B4F-3C5AC483DFF5Q37260388-837C786C-D42E-49FF-BFDB-F61857FA188FQ37355530-177E4FC2-6F4E-44F4-91A5-EB6AF6575AABQ37378913-7E4EB9FA-9607-4189-AF3E-C8EF95DB65C7Q37390380-B2790CD1-C7DA-4CD0-A56C-DB280E88F80FQ37528458-83D7D40F-ED4A-4AC4-A3C2-2B7B9EDC1903Q37541225-E7B7F1E4-56CD-4C32-991F-73F6F89DD204Q37715878-0DDEB3E8-7E1E-414E-8E2C-2DEF7D77F7BBQ37940977-D8356B41-5716-4E2D-8DE0-DE7455769DBDQ38033554-C6788AE5-68A7-4476-99DC-08545B4D0C6EQ39275394-FB399F3A-6045-4B3A-A7C9-00C4CBB0F269Q41921388-3586F76E-9B72-4641-B4CA-4F99B21B8C6F
P2860
New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
New insights into the mechanis ...... nd anti-inflammatory cytokine.
@en
type
label
New insights into the mechanis ...... nd anti-inflammatory cytokine.
@en
prefLabel
New insights into the mechanis ...... nd anti-inflammatory cytokine.
@en
P1433
P1476
New insights into the mechanis ...... nd anti-inflammatory cytokine.
@en
P2093
P304
P356
10.1053/GAST.1997.V112.PM9041265
P407
P577
1997-03-01T00:00:00Z